Feed/Companies/Eikon Therapeutics

Eikon Therapeutics

As of 14 Oct 2026, Eikon Therapeutics has raised $350.7M across 1 verified round on record; latest: $350.7 million Series D, announced 26 Feb 2025.

BUILT ON

Visit site

Eikon is a late-stage clinical biopharmaceutical company focused on inventing and developing breakthrough therapeutics for serious illnesses through innovative scientific and engineering approaches.

eikontx.comHAYWARD, Calif.

LATEST ROUND

Series D

$350.7M · 2025-02-26

RAISED ON RECORD · USD

$350.7M

1 verified round · $1.1B to date, as reported

INVESTORS

no lead named

SOURCES

from 2 publishers

Rounds

[ 1

Feed/Companies

Company

Every round on record, with the sources behind each and the investors on them.

BUILT ON

Series D

$350.7M · 2025-02-26

[ HISTORY ]

lead not stated

Round	Amount	Announced	Lead	Buzz
Series D [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$350.7M $1.1B to date	2025-02-26	not stated	No recent discussion
2 sources [ VERIFIED · CORRECTED ] read against 2 sources The company release states $350.7 million; the secondary article rounds this to $350M, so the release's figure wins. The release says the financing was led by existing investors but names no specific lead firm.

Eikon Therapeutics

Rounds

Company

Rounds

Sources

Profile

Investors

Eikon Therapeutics

Rounds

Profile

Sources

Series D$350.7M2025-02-262 sources

Investors

Series D$350.7M2025-02-2610 investors